Page last updated: 2024-12-08

hygrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hygrine: RN given refers to (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hygrine : A 1-(1-methylpyrrolidin-2-yl)acetone that has R configuration. It is a pyrrolidine alkaloid found in the coca plant, Erythroxylum coca. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Erythroxylumgenus[no description available]ErythroxylaceaeA plant family of the order Linales, subclass Rosidae, class Magnoliopsida best known for the coca plant.[MeSH]

Cross-References

ID SourceID
PubMed CID440933
CHEBI ID46750
SCHEMBL ID335689
MeSH IDM0065601

Synonyms (27)

Synonym
C06179
hygrine
(+)-hygrine
496-49-1
(r)-1-(1-methyl-2-pyrrolidinyl)-2-propanone
(+)-n-methyl-2-acetonylpyrrolidine
1-[(2r)-1-methylpyrrolidin-2-yl]propan-2-one
CHEBI:46750
(r)-hygrine
(r)-(+)-hygrine
1-[(2r)-1-methylpyrrolidin-2-yl]acetone
unii-49h1lnm62x
49h1lnm62x ,
1-(1-methyl-2-pyrrolidinyl)-2-propanone
einecs 207-822-0
AKOS016023684
SCHEMBL335689
2-propanone, 1-((2r)-1-methyl-2-pyrrolidinyl)-
hygrine, (+)-
1-((2r)-1-methyl-2-pyrrolidinyl)-2-propanone
hygrine [mi]
n-methyl-2-acetonylpyrrolidine, (r)-
ADKXZIOQKHHDNQ-MRVPVSSYSA-N
hygrin
DTXSID40894081
Q2376404
(r)-1-(1-methylpyrrolidin-2-yl)propan-2-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrrolidine alkaloid
1-(1-methylpyrrolidin-2-yl)acetoneA methyl ketone that is acetone in which one of the hydrogens is replaced by a 1-methylpyrrolidin-2-yl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
superpathway of hyoscyamine and scopolamine biosynthesis434
hyoscyamine and scopolamine biosynthesis422
calystegine biosynthesis011
tropane alkaloids biosynthesis028
superpathway of hyoscyamine (atropine) and scopolamine biosynthesis039
Calystegine biosynthesis06

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's0 (0.00)18.2507
2000's4 (23.53)29.6817
2010's8 (47.06)24.3611
2020's1 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.50 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (17.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (82.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]